Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease
Evaluation of Everolimus-Eluting Stents (The K-XIENCE Registry)
The objective of this study is to evaluate effectiveness and safety of everolimus-eluting stents (XIENCE, Abbott) in the "real world" daily practice as compared with first-generation drug-eluting stents (sirolimus-eluting stents).
- Trial name
- NCT01350869
- Testing
- Xience
- Where
- South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seung-Jung Park
Coronary Atherosclerosis
Bifurcation Lesion Analysis and STenting / BLAST
The purpose of this research study is to determine if Intravascular Ultrasound (IVUS) grayscale and VH (Virtual Histology)-IVUS pre-stenting can assess more accurately the location, amount, and type of a blockage than angiogram…
- Trial name
- BLAST (NCT02316782)
- Testing
- Blinded IVUS assessment, Nonblinded IVUS
- Where
- 10 sites in United States, Denmark and 6 more
- Volunteers
- 195 people
- Sponsor
- Volcano Corporation
Coronary Heart Disease
Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries
The study is a randomised comparison of recanalisation of chronic occluded coronary arteries with implantation of Sirolimus eluting stents and medical therapy.
- Trial name
- REVASC (NCT01924962)
- Testing
- revascularisation
- Where
- Germany
- Volunteers
- 205 people
- Sponsor
- University Heart Center Freiburg - Bad Krozingen
Coronary Artery Disease
Comparison of Neointimal Coverage Between Zotarolimus Eluting Stent and Everolimus Eluting Stent
Stent thrombosis is an important issue in drug eluting stents. Incomplete endothelial coverage and neointimal coverage over strut after drug eluting stent (DES) implantation could be a possible cause of stent thrombosis.
- Trial name
- COVER OCT (NCT00894062)
- Testing
- Zotarolimus eluting stent (Endeavor resoulte - ZES resolute), Everolimus eluting stent (Xience - EES)
- Where
- 3 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Coronary Artery Disease, Stable Angina
Comparison of Drug Eluting Balloon and Drug Eluting Stent
The purpose of this study is to evaluate the safety and efficacy of Drug-Eluting Balloon first and then bare metal stent compared with drug-eluting stent for treatment of de novo lesions (DEB first).
- Conditions
- Coronary Artery Disease, Stable Angina, Unstable Angina, NSTEMI
- Trial name
- DEBfirst (NCT01539603)
- Testing
- Drug eluting balloon + Bare metal stent, drug eluting stent (Zotarolimus-eluting stent)
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Seoul National University Bundang Hospital
Coronary Artery Disease, Stent Restenosis
MACE in Different Drug-Eluting Stents
In this retrospective cohort study, all patients from Iranian registry were recruited and follow up after 5 years were recorded for MACE, and its relation to type and demographic data were evaluated
- Trial name
- NCT06470529
- Testing
- drug eluting stents
- Where
- Iran
- Volunteers
- 4,159 people
- Sponsor
- Shiraz University of Medical Sciences
Coronary Artery Disease
In Stent ELUTES Study
This trial will compare the long term safety and effectiveness of the V Flex Plus PTX Drug Eluting coronary stent with conventional treatment for in-stent restenosis for coronary arteries.
- Trial name
- ELUTES II (NCT00225680)
- Testing
- drug eluting coronary stent
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease, Diabetes
Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES
The objective of the study is to compare angiographic and clinical performance of Abluminus DES+ versus Everolimus-eluting DES in patients with diabetes mellitus.
- Trial name
- NCT03399994
- Testing
- device implantation during coronary angioplasty
- Where
- 6 sites in Italy
- Volunteers
- 137 people
- Sponsor
- Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Coronary Artery Disease
The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions
The purpose of this study is to assess the equivalence in safety and efficacy of the Endeavor Drug Eluting Coronary Stent System when compared to the Taxus Paclitaxel-Eluting Coronary Stent System for the treatment of single de…
- Trial name
- ENDEAVOR IV (NCT00217269)
- Testing
- Coronary Artery Stenting
- Where
- United States
- Volunteers
- 1,548 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
Optical Coherence Tomography for EVERolimus Eluting STent
Compared with bare metal stents (BMS), both paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES) significantly reduce angiographic restenosis and the need for repeat revascularization in coronary arteries across a…
- Trial name
- OCTEVEREST (NCT01146080)
- Testing
- Promus Element, Promus
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Coronary Artery Disease
SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent
Bioresorbable polymer drug eluting stents (DES) are an indisputable improvement over first-generation DES with promising results on long-term adverse events. But the thicker polymer and/or strut may hinder its deliverability.
- Trial name
- NCT02150876
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- University of Freiburg
Coronary Artery Disease, Cardiac Death
BioFreedom QCA Study in CAD Patients
This study aims to demonstrate that the BioFreedom™ Cobalt Chromium Drug Coated Stent is non-inferior to the market authorized BioFreedom™ Stainless Steel Stent with respective to efficacy and shows a similar safety profile.
- Conditions
- Coronary Artery Disease, Cardiac Death, Myocardial Infarction
- Trial name
- BioFreedomQCA (NCT03307213)
- Testing
- BioFreedom™ CoCr Biolimus A9™ stent, BioFreedom™ SS Biolimus A9™ stent
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 200 people
- Sponsor
- Biosensors Europe SA
Coronary Disease, Coronary Artery Disease
SPIRIT II: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
Prospective, randomized, active-control, single blind, parallel two-arm multi-center clinical trial comparing XIENCE V® Everolimus Eluting Coronary Stent System to the approved commercially available active control TAXUS™…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT II (NCT00180310)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 32 sites in Austria, Belgium and 11 more
- Volunteers
- 300 people
- Sponsor
- Abbott Medical Devices
Pulmonary Stenosis, Pulmonary Regurgitation
Pulmonary Artery Repair With Covered Stents
The Covered Cheatham-Platinum Stent (CCPS) is being study for repair of tears that occur in the pulmonary artery during dilation (enlargement) of a conduit (passageway) connecting the right ventricle of the heart to the pulmonary…
- Conditions
- Pulmonary Stenosis, Pulmonary Regurgitation, Tetralogy of Fallot
- Trial name
- PARCS (NCT01824160)
- Testing
- Repair of RV-PA Conduit Disruption
- Where
- 38 sites in United States
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins University
Coronary Artery Disease
Duration of Clopidogrel Therapy After Drug-Eluting Stent (DES-LATE)
This is randomized-controlled trial to evaluate the difference of composite of cardiac death, myocardial infarction, or Stroke between the dual antiplatelet therapy group and the aspirin monotherapy group after 1-year of…
- Trial name
- DES-LATE (NCT01186146)
- Testing
- Aspirin monotherapy, Aspirin,Clopidogrel
- Where
- 19 sites in South Korea
- Volunteers
- 5,000 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Romania Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01593059
- Where
- 4 sites in Romania
- Volunteers
- 13 people
- Sponsor
- Biotronik Vertriebs-GmbH
Coronary Artery Disease
Registry to Evaluate Efficacy of Xience/Promus Versus Cypher in Reducing Late Loss After Stenting
The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the everolimus-eluting stent (EES) and to determine clinical device and procedural success during commercial use of EES…
- Trial name
- NCT00960648
- Testing
- Xience/Promus, Cypher
- Where
- 18 sites in South Korea
- Volunteers
- 3,056 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions
The objective of this study is to evaluate the effectiveness and safety of the CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-Wire (OTW) Stent Delivery System (SDS) in patients with de novo native coronary…
- Trial name
- NCT00231283
- Testing
- CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
JACTAX LD Drug Eluting Stent Trial
Prospective, multi-center, randomized trial. A maximum of 130 patients will be enrolled, in a 2:1 ratio to receive either the JACTAX LD stent or the TAXUS™ Libertè™ stent to evaluate the efficacy of the product.
- Trial name
- NCT00754975
- Testing
- JACTAX LD DES, TAXUS™ Libertè™ DES
- Where
- 5 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Coronary Stenosis
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis
BACKGROUND: Bifurcated lesions are a challenging subset in percutaneous coronary interventions (PCI). The selection of the type of DES and the technique for stent implantation have not been clarified.
- Trial name
- SEA-SIDE (NCT00697372)
- Testing
- Sirolimus eluting stent, Everolimus eluting stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart